Back to results
US 9,597,380 B2Granted
Terminally modified RNA
AssigneeModernaTX, Inc.
InventorsTirtha Chakraborty, Stephane Bancel, Stephen G. Hoge, Atanu Roy, Antonin de Fougerolles, Noubar B. Afeyan
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
Claims13
A method of reducing a protein antigen-mediated immune response in a subject, comprising administering to the subject a composition comprising a chemically modified mRNA and a pharmaceutically acceptable carrier, wherein the chemically modified mRNA comprises
- (a) a 5′ untranslated region (5′ UTR);
- (b) a region of linked nucleosides encoding said protein antigen;
- (c) a 3′ untranslated region (3′ UTR) comprising at least one miR-142-3p microRNA binding site;
- and
- (d) a 3′ tailing region of linked nucleosides,
- wherein the chemically modified mRNA comprises fully modified 1-methyl pseudouridine nucleosides, and optionally comprises fully modified 5′ methyl-cytidine nucleosides, thereby reducing the protein antigen-mediated immune response in the subject.
3 more elements
Dependencies are inferred from the claim text.